AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ABACAVIR SULFATE AND LAMIVUDINE

8 registrations across 4 African markets— 6 active

Markets with ABACAVIR SULFATE AND LAMIVUDINE

Recent registrations

Brand / ProductMarketHolderStatusExpires
Abacavir and Lamivudine Dispersible Tablets 120…
Dispersible Tablet
🇰🇪KenyaMicro Labs LimitedactiveOct 2030
Abacavir Sulfate and Lamivudine Tablets 600/300mg
Tablets
🇷🇼RwandaHetero Labs LimitedactiveAug 2029
ABACAVIR_LAMIVUDINE 600/300MG TABLET
TABLET
🇲🇼MalawiexpiredMar 2025
ABACAVIR_LAMIVUDINE 60/30MG TABLET
TABLET
🇲🇼MalawiexpiredMar 2024
Abacavir and Lamivudine Tablets USP 600 mg/300 mg
Oral tablet
🇹🇿TanzaniaMacleods Pharmaceuticals Limitedactive
Abacavir (as sulfate) / Lamivudine Dispersible Tablets 120mg /60 mg
Tablets
🇹🇿TanzaniaMylan Laboratories Limitedactive
Abacavir (as Sulfate) and Lamivudine Dispersible Tablets 120/60 mg
Dispersible Tablets
🇹🇿TanzaniaCipla Limitedactive
Abacavir Sulfate 600mg and Lamivudine Tablets 300mg
Film Coated Tablet
🇹🇿TanzaniaMylan Laboratories Limitedactive

ABACAVIR SULFATE AND LAMIVUDINE in Africa — Regulatory Overview

ABACAVIR SULFATE AND LAMIVUDINE is registered across 4 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tanzania, Malawi, Kenya, Rwanda. AfricaRegulatory refreshes this data daily from official government sources.

Of the 8 registrations, 6 (75%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.